Yuqian Ren

Dr. Yuqian Ren


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
QZQiu-Yue Zhai
Qiu-Yue Zhai
YRYuqian Ren
Yuqian Ren
QNQin-Shuai Ni
Qin-Shuai Ni
ZSZhenhua Song
Zhenhua Song
KGKe-Li Ge
Ke-Li Ge
YGYun-Liang Guo
Yun-Liang Guo
Ischemic stroke is a common cerebrovascular disease and recovering blood flow as early as possible is essential to reduce ischemic damage and maintain neuronal viability, but the reperfusion process usually causes additional damage to the brain tissue in the ischemic area, namely ischemia reperfusion injury. The accumulated studies have revealed that transplantation of exogenous neural stem cells (NSCs) is an ideal choice for the treatment of ischemia reperfusion injury. At present, the source and efficacy of exogenous NSCs after transplantation is still one of the key issues that need to be resolved. In this study, human umbilical cord mesenchymal stem cells (hUC-MSCs) were obtained and induced into NSCs byadding growth factor and neuregulin1β (NRG1β) was introduced during the differentiation process of NSCs. Then, the rat middle cerebral artery occlusion/reperfusion (MCAO/R) models were established, and the therapeutic effects were evaluated among groups treated by NRG1β, NSCs and NSCs pretreated with 10 nM NRG1β (NSCs-10 nM NRG1β) achieved through intra-arterial injection. Our data show that the NSCs-10 nM NRG1β group significantly improves neurobehavioral function and infarct volume after MCAO/R, as well as cerebral cortical neuron injury, ferroptosis-related indexes and mitochondrial injury. Additionally, NSCs-10 nM NRG1β intervention may function through regulating the p53/GPX4/SLC7A11 pathway, and reducing the level of ferroptosis in cells, further enhance the neuroprotective effect on injured cells.

17 April 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YRYuqian Ren
Yuqian Ren
ZLZhenchao Liu
Zhenchao Liu
LWLinhai Wei
Linhai Wei
YWYinuo Wang
Yinuo Wang
YWYanzhi Wang
Yanzhi Wang
ZMZegang Ma
Zegang Ma
Inflammation, as a basic pathological process, is critically implicated in the pathogenesis and progression of numerous diseases. Picrorhizae rhizoma is a type of traditional Chinese medicine with prominent anti-inflammatory effect. And picroside II, a representative iridoid compound, is the major bioactive constituent of Picrorhizae rhizoma. Over recent decades, picroside II has garnered extensive research interest owing to its remarkable pharmacological efficacy. Accumulating evidence has validated that picroside II exerts significant anti-inflammatory effects in the prevention and treatment of various systemic diseases. This review comprehensively summarizes and updates the latest research advances of picroside II, systematically elaborating its anti-inflammatory molecular mechanisms, pharmacokinetic profiles, and safety evaluation characteristics. The integrated data and analyses in this review aim to provide solid theoretical support, reliable evidence, and novel insights for the in-depth mechanism research, rational medicinal development, and future clinical translation and application of picroside II.